Literature DB >> 21151547

Cardiovascular outcomes in patients with normal and abnormal 24-hour ambulatory blood pressure monitoring.

P Iqbal1, Louise Stevenson.   

Abstract

Introduction. 24-hour ambulatory blood pressure monitoring (ABPM) plays an important role in assessing cardiovascular prognosis, through presence or absence of ABPM-related prognostic features. Objectives. To study relationship between 24-hour ABPM and cardiovascular outcomes in patients from Chesterfield Royal Hospital. Material and Methods. Over 12 months from the 1st of August 2002, 1187 individuals had 24-hour ABPM performed. Cardiovascular outcomes were studied in a subset (297) of the original cohort, made up by every 4th consecutive subject. The following ABPM-related prognostic features were studied-high day time systolic and diastolic BP (≥135, ≥85 mmHg), high night time systolic and diastolic BP (≥120 mmHg, ≥75 mmHg), absence of nocturnal dip (≤10% fall in night time SBP), high early morning SBP (≥140 mmHg), and morning surge (≥20/15 mmHg). The cardiovascular outcomes studied in the fourth table included fatal and nonfatal MI, new diagnosis of angina, acute coronary syndrome, sudden cardiac death, cardiac arrhythmias, acute LVF, cerbrovascular events, peripheral vascular disease, abdominal aortic aneurysm, and CKD stage 3 or above. Results. Over a followup period of 2015 ± 116 days (1720-2305 days) 82 cardiovascular events occurred in 61 subjects. Cardiac arrhythmias were the most common CV outcome (34 events) followed by cerebrovascular events (15). Statistically significant associations found were between cerebrovascular events and absent nocturnal dip ≤ 10% (P = .05) and high day time DBP (P = .029), peripheral vascular disease and morning surge ≥ 20/15 mmHg (P = .014), cardiac arrhythmias and high day time and night time DBP (P = .009 and .033, resp.). Conclusion. Significant associations were found between cerebrovascular events and absent nocturnal dip ≤ 10% and high day time DBP, peripheral vascular disease and morning surge ≥ 20/15 mmHg, cardiac arrhythmias and high day time and night time DBP.

Entities:  

Year:  2010        PMID: 21151547      PMCID: PMC2997497          DOI: 10.4061/2011/786912

Source DB:  PubMed          Journal:  Int J Hypertens            Impact factor:   2.420


1. Introduction

24-hour ABPM plays an important role in determining cardiovascular prognosis and has been shown to be a better predictor of cardiovascular morbidity and mortality as compared to office blood pressure measurements [1-3].

2. Objectives

The objective was to study the relationship between 24 H ABPM and cardiovascular outcomes in patients from Chesterfield Royal hospital. It was a retrospective observational study based on review of clinical case notes.

3. Material and Methods

Over 12 months from the 1st of August 2002, 1187 individuals had 24-hour ABPM performed. These individuals represented a typical spectrum of patients attending for 24 H ABPM with blood pressure at different stages and with varying durations of hypertension. Cardiovascular outcomes were studied in a subset (297) of the original cohort, made up by every 4th consecutive subject. The inclusion criteria were as follows. Individuals must have one of the recognized indications for 24-hour ABPM, as outlined in Table 1.
Table 1
Indications for 24-hour ABPM
Borderline hypertension
Variable clinic blood pressure
Suspected white coat hypertension
Suspected white coat effect
Resistant hypertension
Hypertension in pregnancy
Hypertension in elderly patients
Evaluation of symptoms suggesting postural hypotension
Evaluation of symptoms suggesting drug induced hypotension
Blood pressure evaluation in patients with the suspected or proven autonomic dysfunction
As an overall guide to hypertension treatment
As a prognostic cardiovascular tool
Every 4th consecutive patient was entered into the study, giving a total of 297, patients. Table 2 outlines demographics and blood pressure criteria between the original cohort and the study cohort.
Table 2

Comparison of cohorts 1 and 2.

Cohort 1: 1187 patientsCohort 2: 245 patientsStatistical significance
Age59.13 yrs ± 13.960.1 yrs ± 13.6NS

N%N%
Male54746.110743.7NS
Female64053.913856.3

Adverse featuresN%N%
 High PP ≥ 50 mmHg73662.016165.7NS
 High DSBP ≥ 135 mmHg70359.214659.6NS
 High DDBP ≥ 85 mmHg51543.410141.2NS
 High NSBP ≥ 120 mmHg63954.013856.3NS
 High NDBP ≥ 75 mmHg40434.08333.9NS
 Absent ND ≤ 10%67757.013454.7NS
 High EM SBP ≥ 140 mmHg39633.47430.2NS
 High MS ≥ 20/15 mmHg55246.510643.3NS

 No. adverse featuresN%N%NS
 0635.3135.3NS
 11149.6229.0NS
 217714.93514.3NS
 316814.24317.6NS
 417614.83514.3NS
 518215.33715.1NS
 615112.73012.2NS
 711910.0239.4NS
 8373.172.9NS

Adverse Features groupsN%N%
 0–235429.87028.6
 3–552644.311546.9NS
 6–830725.96024.5

There was no significant difference between the two cohorts.

(Oneway Anova was used for comparing cohort 1 and 2 ages; cross-tabulation with chi-square Test was used to compare adverse features; no. of adverse features and adverse features groups and gender).

The exclusion criteria were as follows. Clinical case notes to study prognostic information were not available from 52 subjects and they were excluded leaving 245 patients. The following ABPM-related prognostic features were studied (Table 3) high day time systolic and diastolic BP (≥135, ≥85 mmHg), high night time systolic and diastolic BP (≥120 mmHg, ≥75 mmHg), absence of nocturnal dip (≤10% fall in night time SBP), high early morning SBP (≥140 mmHg), and morning surge (≥20/15 mmHg rise in the first two morning readings from 7 AM as compared to average night time BP) [4]. The cardiovascular outcomes studied (Table 4) included fatal and nonfatal MI, new diagnosis of angina, acute coronary syndrome, sudden cardiac death, cardiac arrhythmias, acute LVF, cerebrovascular events, peripheral vascular disease, abdominal aortic aneurysm, and CKD stage 3 or above.
Table 3

List of adverse prognostic features noted on 24-hour ABPM.

Adverse featuresValues*
High pulse pressure≥50 mmHg
High day systolic BP≥135 mmHg
High day diastolic BP≥85 mmHg
High night systolic BP≥120 mmHg
High night diastolic BP≥75 mmHg
Absent nocturnal dip≤10 %
High early morning systolic BP≥140 mmHg
High morning surge≥20/15 mmHg

∗K. Madin and P. Iqbal (PMJ 2006)

Table 4
List of CV outcomes, detected on retrospective case notes review.
Non-fatal ST segment elevated MI (ESC/ACC 2000)
Non-fatal non-ST segment elevated MI (ACC/AHA2007)
Non-fatal acute coronary syndrome
New diagnosis of angina pectoris (typical history and positive treadmill cardiac test)
Fatal ST segment elevated MI (ESC/ACC 2000)
Fatal non-ST segment elevated MI
Fatal acute coronary syndrome
Sudden cardiac death (ACC/AHA 2006)
Cardiac arrhythmias (resting or ambulatory ECG documented evidence of any supraventricular and ventricular arrhythmias)
Acute left ventricular failure (typical clinical history backed by chest X-ray finding)
Fatal or non-fatal cerebrovascular event (typical clinical history and CT/MRI findings)
Renal failure (CKD stage 3 or above, developing during the followup period, according to K/DOQI 2002)
Peripheral vascular disease, typical symptoms supported by bilateral lower limb arterial Doppler
Fatal or non-fatal abdominal aortic aneurysm ≥ 4 cm on abdominal ultrasound done in the followup period

4. Results

Over a followup period of 2015 ± 116 days (1720–2305 days) 82 cardiovascular events occurred in 61 subjects. Cardiac arrhythmias were the most common CV outcome (34 events) followed by cerebrovascular events (15). Statistically significant associations found were between cerebrovascular events and absent nocturnal dip ≤  10% (P = .05) and high day time DBP (P = .029), peripheral vascular disease and morning surge ≥ 20/15 mmHg (P = .014), cardiac arrhythmias and high day time and night time DBP (P = .009 and, 033, resp.). Age and gender did not have any statistical associations with the outcomes.

5. Discussion

In this study, cardiac arrhythmias were the most commonly observed event accounting for 13.9% of the total events. Atrial fibrillation was the most common cardiac arrhythmia seen in 14/38 (52.9%) patients with cardiac arrhythmias, followed by symptomatic ventricular ectopics in 13 subjects (38.2%) and supraventricular tachycardia and sinoatrial pause in 1 patient each. Atrial fibrillation is being recognised as a common problem in patients with hypertension. It has been shown to be associated with systolic hypertension [4] and high pulse pressure [5]. Atrial fibrillation may complicate even mildly raised blood pressure, and it would be reasonable to assume that there is no threshold below which the risk of atrial fibrillation is not increased [6]. To the best of our knowledge, our study is the first one to show an increased risk of atrial fibrillation with high day time and night time diastolic blood pressure. Having said that, one of the recent Japanese studies has shown that control of both systolic and diastolic blood pressure is important in reducing risk of new onset atrial fibrillation [7]. Over the years a variety of other risk factors for atrial fibrillation have been identified such as large left-atrial size, obesity, thyrotoxicosis, and high alcohol. Our study does not take into account these risks factors. The exact mechanism for atrial fibrillation in hypertensive subjects is not understood but is believed to be related to left ventricular hypertrophy and an increase in left-atrial size [8], left-atrial fibrosis secondary to high systolic blood pressure [9] and changes in autonomic tone with higher in-treatment heart rate on serial ECGs [10]. Atrial fibrillation is an important cardiovascular risk factor for thromboembolic cardiovascular disease and adds to the existing risk from hypertension itself. Treatment of hypertension exclusively with ACE inhibitors, angiotensin-II-receptor blockers, and beta blockers was shown to be associated with a lower risk of developing atrial fibrillation than current exclusive therapy with calcium-channel blockers [11]. In summary, our study shows that diastolic hypertension plays an important role in leading to cardiac arrhythmias, in particular atrial fibrillation, and should be treated as vigorously as systolic hypertension. The study's main limitation is that it did not take into account presence or absence of other cardiovascular risk factors, such as diabetes mellitus, smoking, hyperlipidaemia, or family history, and has relied entirely on blood pressure criterias. The authors would like to acknowledge that this may have had bearing on some of the findings.
Table 5
82-Cardiovascular outcomes in 61 patientsFrequency
Myocardial infarction6 (2.4%)
Acute coronary syndrome3(1.2%)
New diagnosis of angina pectoris4(1.6)
Sudden cardiac death0
Cardiac arrhythmias34 (13.9%)
Acute left ventricular failure0
Fatal or non-fatal cerebrovascular event15 (6.5%)
Peripheral vascular disease5 (2%)
Fatal or non-fatal abdominal aortic aneurysm1 (0.4%)
Renal failure (CKD ≥ stage 3)14 (5.7%)

Statistically significant associations (Fisher exact test)
Cerebrovascular events and absent nocturnal dip ≤ 10%P = .50
Cerebrovascular events high day time DBPP = .029
Peripheral vascular disease and morning surge ≥ 20/15 mmHgP = .014
Cardiac arrhythmias and high day timeP = .009
Cardiac arrhythmias and night time DBPP = .033
  11 in total

1.  Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study.

Authors:  Eamon Dolan; Alice Stanton; Lut Thijs; Kareem Hinedi; Neil Atkins; Sean McClory; Elly Den Hond; Patricia McCormack; Jan A Staessen; Eoin O'Brien
Journal:  Hypertension       Date:  2005-06-06       Impact factor: 10.190

2.  Pulse pressure and risk of new-onset atrial fibrillation.

Authors:  Gary F Mitchell; Ramachandran S Vasan; Michelle J Keyes; Helen Parise; Thomas J Wang; Martin G Larson; Ralph B D'Agostino; William B Kannel; Daniel Levy; Emelia J Benjamin
Journal:  JAMA       Date:  2007-02-21       Impact factor: 56.272

3.  Incidence of and risk factors for atrial fibrillation in older adults.

Authors:  B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

4.  Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study.

Authors:  Beat A Schaer; Cornelia Schneider; Susan S Jick; David Conen; Stefan Osswald; Christoph R Meier
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

5.  Blood pressure control and the reduction of left atrial overload is essential for controlling atrial fibrillation.

Authors:  Yasuko Tanabe; Yuichiro Kawamura; Naka Sakamoto; Nobuyuki Sato; Kenjiro Kikuchi; Naoyuki Hasebe
Journal:  Int Heart J       Date:  2009-07       Impact factor: 1.862

6.  Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.

Authors:  Eamon Dolan; Alice V Stanton; Simon Thom; Mark Caulfield; Neil Atkins; Gordon McInnes; David Collier; Patrick Dicker; Eoin O'Brien
Journal:  J Hypertens       Date:  2009-04       Impact factor: 4.844

7.  Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes.

Authors:  Kazuo Eguchi; Thomas G Pickering; Satoshi Hoshide; Joji Ishikawa; Shizukiyo Ishikawa; Joseph E Schwartz; Kazuyuki Shimada; Kazuomi Kario
Journal:  Am J Hypertens       Date:  2008-02-21       Impact factor: 2.689

8.  Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.

Authors:  S M Vaziri; M G Larson; E J Benjamin; D Levy
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

9.  Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women.

Authors:  David Conen; Usha B Tedrow; Bruce A Koplan; Robert J Glynn; Julie E Buring; Christine M Albert
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

10.  Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.

Authors:  Peter M Okin; Kristian Wachtell; Sverre E Kjeldsen; Stevo Julius; Lars H Lindholm; Björn Dahlöf; Darcy A Hille; Markku S Nieminen; Jonathan M Edelman; Richard B Devereux
Journal:  Circ Arrhythm Electrophysiol       Date:  2008-12-02
View more
  8 in total

1.  Morning Blood Pressure Surge and Cardiovascular Disease Events and All-Cause Mortality in Blacks: The Jackson Heart Study.

Authors:  John N Booth; Byron C Jaeger; Lei Huang; Marwah Abdalla; Mario Sims; Mark Butler; Paul Muntner; Daichi Shimbo
Journal:  Hypertension       Date:  2020-02-03       Impact factor: 10.190

2.  Can acupuncture affect the circadian rhythm of blood pressure? A randomized, double-blind, controlled trial.

Authors:  Hye-Mi Kim; Seung-Yeon Cho; Seong-Uk Park; Il-Suk Sohn; Woo-Sang Jung; Sang-Kwan Moon; Jung-Mi Park; Chang-Nam Ko; Ki-Ho Cho
Journal:  J Altern Complement Med       Date:  2012-08-20       Impact factor: 2.579

Review 3.  Prognostic significance of the morning blood pressure surge in clinical practice: a systematic review.

Authors:  James Peter Sheppard; James Hodgkinson; Richard Riley; Una Martin; Susan Bayliss; Richard J McManus
Journal:  Am J Hypertens       Date:  2014-10-14       Impact factor: 2.689

Review 4.  Decoding white coat hypertension.

Authors:  Dennis A Bloomfield; Alex Park
Journal:  World J Clin Cases       Date:  2017-03-16       Impact factor: 1.337

5.  Comparison of the antihypertensive efficacy of morning and bedtime dosing on reducing morning blood pressure surge: A protocol for systemic review and meta-analysis.

Authors:  Peng Zhang; Mei-Ying Jin; Xu-Yu Song; Zhao Wang; Yue-Hua Jiang; Chuan-Hua Yang
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

6.  Nurse-driven training courses: impact on implementation of ambulatory blood pressure monitoring.

Authors:  Estel Félez-Carrobé; Maria Sagarra-Tió; Araceli Romero; Montserrat Rubio; Lourdes Planas; María José Pérez-Lucena; Montserrat Baiget; Cristina Cabistañ; Jordi Félez
Journal:  Open Nurs J       Date:  2013-04-05

7.  The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension: A 12-week prospective randomized, open-label study trial.

Authors:  Marta Walczak-Gałęzewska; Monika Szulińska; Ewa Miller-Kasprzak; Danuta Pupek-Musialik; Paweł Bogdański
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 8.  Diabetic patients with chronic kidney disease: Non-invasive assessment of cardiovascular risk.

Authors:  Nejc Piko; Sebastjan Bevc; Robert Ekart; Tadej Petreski; Nina Vodošek Hojs; Radovan Hojs
Journal:  World J Diabetes       Date:  2021-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.